A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Antiviral Efficacy of PPI-668 in Healthy Volunteers and Patients With HCV Genotype-1 Infection.

Trial Profile

A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Antiviral Efficacy of PPI-668 in Healthy Volunteers and Patients With HCV Genotype-1 Infection.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2012

At a glance

  • Drugs Ravidasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jun 2012 Data from the phase Ib portion of this trial have been presented in a Presidio Pharmaceuticals media release.
    • 26 Jun 2012 Status changed from recruiting to completed, according to a Presidio Pharmaceuticals media release.
    • 19 Apr 2012 Interim data were reported in a Presidio media release. Recruitment of patients with genotype 2a or 3a hepatitis C is ongoing.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top